Health Security and Smallpox Potential

Dr. Phillip Gomez, Ph.D., CEO at SIGA Technologies, Inc., discusses how the field of Health Security has transformed after the anthrax attacks in the United States in late 2001.  He also talks about the potential for a smallpox bioterror attack and how would it compare with the current COVID-19 pandemic. 

Phillip Gomez has served as SIGA’s Chief Executive Officer since 2016. Dr. Gomez brings more than 25 years of experience in infectious disease and pharmaceutical business. Prior to joining SIGA, Phil was a Principal in the Pharma & Life Sciences Management Consulting Practice at PwC and PRTM Management Consultants, where he led development and execution of business strategies for leading pharmaceutical companies, governmental agencies, academic medical centers, and foundations. Dr. Gomez joined PRTM from the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases at the NIH, where he established the Vaccine Production Program against HIV, SARS, Ebola, West Nile Virus, and Influenza. Prior to that, he spent more than nine years in the pharmaceutical industry at Abbott Laboratories, Sanofi Pasteur, and Baxter in positions of increasing responsibility, leading process/product development initiatives for the development of multiple biologics. Dr. Gomez holds a B.A. degree from Dartmouth College, a Ph.D. in chemical engineering from Lehigh University, and an M.B.A. from the Smith School of Business at the University of Maryland.